Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia

Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia

Joyce C. de Mello, Vivian W. R. Moraes, Carolina M. Watashi, Deyse C. da Silva, Leide P. Cavalcanti, Margareth K. K. D. Franco, Fabiano Yokaichiya, Daniele R. de Araujo, Tiago Rodrigues

ARTIGO

Inglês

The development of specific tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia (CML). However, chemoresistance of tumor cells to TKIs has already been described, and several mechanisms account for the multidrug resistance (MDR) phenotypes, including the over...

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ

Fechado

Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia

Joyce C. de Mello, Vivian W. R. Moraes, Carolina M. Watashi, Deyse C. da Silva, Leide P. Cavalcanti, Margareth K. K. D. Franco, Fabiano Yokaichiya, Daniele R. de Araujo, Tiago Rodrigues


										

Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia

Joyce C. de Mello, Vivian W. R. Moraes, Carolina M. Watashi, Deyse C. da Silva, Leide P. Cavalcanti, Margareth K. K. D. Franco, Fabiano Yokaichiya, Daniele R. de Araujo, Tiago Rodrigues

    Fontes

    Pharmacological research

    Vol. 111 (Sep., 2016), p. 102-112